GeneDx Reports Second Quarter 2025 Financial Results and Business Highlights

GeneDx Reports Second Quarter 2025 Financial Results and Business Highlights

July 29, 2025 | Last Trade: US$101.60 0.35 -0.34

NASDAQ: WGS

Healthcare

Health Technology

Financial Results

VISIT WEBSITE

Reported second quarter 2025 revenues of $102.7 million with 69% year-over-year growth of exome and genome test revenue
Expanded adjusted gross margin to 71% and generated adjusted net income¹ of $15.0 million for the second quarter 2025
Raised guidance to deliver between $400 and $415 million in revenue with between 48% to 52% full year growth in exome and genome revenue
Announced American Academy of Pediatrics (AAP) now recommends pediatricians use exome and genome testing as first-line for children with global developmental delay or intellectual disability
Hosting conference call today at 8:30 a.m. ET

GAITHERSBURG, Md. / Jul 29, 2025 / Business Wire / GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the second quarter of 2025.

“Crossing the $100 million revenue mark and delivering our fourth consecutive profitable quarter is a major milestone for GeneDx, putting us on a path for more growth at scale and enabling us to reach more patients while reducing unnecessary spend across the global healthcare system,” said Katherine Stueland, CEO of GeneDx. “Our strong second quarter performance was driven by our core business, underscoring its strength and resilience. These results, coupled with the ever-expanding opportunities ahead, including general pediatrics, demonstrate that we’re just beginning to deliver on the promise of how our technology can fundamentally change the way genomics can inform healthcare, shifting from reactive to proactive care.”

Second Quarter 2025 Financial Results (Unaudited)^1,2

Revenues

Revenues grew to $102.7 million, an increase of 49% year-over-year.
Exome and genome test revenue grew to $85.9 million, an increase of 69% year-over-year.

Exome and genome volume

Exome and genome test results volume grew to 23,102, an increase of 28% year-over-year.
Exome and genome represented 41% of all tests, up from 31% in the second quarter of 2024.

Gross margin

Adjusted gross margin expanded to 71%, up from 62% in the second quarter of 2024.
- Total GAAP gross margin was 69%.

Operating expenses

Adjusted total operating expenses were $57.8 million, representing 56% of revenue in the second quarter of 2025, compared to 65% of revenue in the second quarter of 2024.
- Total GAAP operating expenses were $61.9 million.

Net Income

Adjusted net income was $15.0 million compared to an adjusted net loss of $2.0 million in the second quarter of 2024.
- GAAP net income was $10.8 million.

Cash position

Cash, cash equivalents, marketable securities and restricted cash was $135.5 million as of June 30, 2025.
Cash flow for the second quarter 2025 primarily included:
- $33.2 million used to acquire Fabric Genomics, net of cash acquired, partially offset by;
- $10.4 million in cash generated from operations.

1.	Revenue and adjusted gross margin growth rates exclude revenue and costs of sales from the exited Legacy Sema4 diagnostic testing business.
2.	Adjusted gross margin, adjusted total operating expenses and adjusted net income/(loss) are non-GAAP financial measures. See appendix for a reconciliation of GAAP to Non-GAAP figures presented.

GeneDx Full Year 2025 Guidance

GeneDx has raised certain elements of its full year 2025 guidance and expects to deliver:

Metric	Previous Guidance	Updated Guidance
Revenue	$360 to $375 million	$400 to $415 million
Growth in exome and genome revenue	30%	48% to 52%
Growth in exome and genome volume	30%	30%
Adjusted gross margin	66% to 68%	68% to 71%
Adjusted net income	Positive each quarter and for full year	Positive each quarter and for full year

Second Quarter 2025 and Recent Business Highlights

Strategic Expansion and Market Access

Announced that the American Academy of Pediatrics now recommends exome and genome sequencing as first-tier tests for children with global developmental delay or intellectual disability, positioning pediatricians to offer exome and genome testing to their patients.
Expanded commercial focus to include calling on providers treating children with inborn errors of immunity (IEI), a group of nearly 500 genetic disorders that impair immune function.
Accelerated adoption of exome and genome sequencing coverage by state Medicaid programs, bringing the total states covering exome or genome sequencing in the pediatric outpatient setting to 35 with the recent addition of Colorado and Maine, and the total states covering rapid genome sequencing in the neonatal intensive care unit (NICU) to 17 with the recent addition of Virginia, Ohio, and Oklahoma.

Innovation & Clinical Leadership

Acquired Fabric Genomics, enabling a hybrid centralized and decentralized model for delivering genomic insights globally.
Published SeqFirst study in the Journal of Pediatrics, showing rapid genomic testing reduced time to diagnosis from about 10 months to 13 days.
Published data in the American Journal of Medical Genetics underscoring GeneDx’s leadership in leveraging artificial intelligence (AI) to increase diagnostic yield and improve healthcare for patients with genetic conditions.

Webcast and Conference Call Details

GeneDx will host a conference call today, July 29, 2025, at 8:30 a.m. Eastern Time. Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the “Events” section of the GeneDx investor relations website at https://ir.genedx.com/.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our future performance, future operations, plans, objectives of management, and our market opportunity, including our expected full year 2025 reported revenue, volume, adjusted gross margin and adjusted net income. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to implement business plans, goals and forecasts, and identify and realize additional opportunities, (ii) the risk of downturns and a changing regulatory landscape in the highly competitive healthcare industry, (iii) the size and growth of the market in which we operate, (iv) our ability to pursue our new strategic direction, and (v) our ability to utilize our artificial intelligence tools that we use in our clinical interpretation platform. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” sections of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 20, 2025, and our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025 and June 30, 2025, filed with the SEC on April 30, 2025 and July 29, 2025, respectively, and other documents filed by us from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and we assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. We do not give any assurance that we will achieve our expectations.

About GeneDx

At GeneDx (Nasdaq: WGS), we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world’s largest rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. For more information, please visit genedx.com and connect with us on LinkedIn, Facebook, and Instagram.

Volume & Revenue ¹

		2Q25		1Q25		4Q24		3Q24			2Q24
Volumes
Whole exome, whole genome		23,102		20,562		20,676		19,262			18,017
Hereditary cancer		2,677		2,725		3,486		4,672			5,482
Other panels		29,894		28,228		30,115		35,095			34,204
Total		55,673		51,515		54,277		59,029			57,703

Revenue ($ millions)
Whole exome, whole genome	$	85.9	$	71.4	$	78.8	$	60.0		$	50.7
Hereditary cancer		1.8		2.2		2.8		3.3			3.8
Other panels		12.1		12.1		12.3		13.8			13.3
Data information		2.0		1.4		1.4		(0.5	)		1.1
Fabric Genomics		0.9		—		—		—			—
Total	$	102.7	$	87.1	$	95.3	$	76.6		$	68.9
Excludes volume and revenue from the exited Legacy Sema4 diagnostic testing business.

Unaudited Select Financial Information (in thousands)

	Three months ended June 30, 2025									Three months ended June 30, 2024
	GeneDx			Other¹			Total			GeneDx			Other¹			Total
Revenue	$	101,784		$	908		$	102,692		$	68,924		$	1,590		$	70,514
Adjusted cost of services		29,964			244			30,208			26,523			145			26,668
Adjusted gross profit (loss)	$	71,820		$	664		$	72,484		$	42,401		$	1,445		$	43,846
Adjusted gross margin %		70.6	%		73.1	%		70.6	%		61.5	%		90.9	%		62.2	%
Other includes revenue and cost of services from the Legacy Sema4 diagnostic testing business for both periods presented. For the three months ended June 30, 2025, Other includes revenue and cost of services from Fabric Genomics.

	Three months ended June 30, 2025
	Reported			Depreciation and amortization			Stock-based compensation expense			Restructuring costs			Change in FV of financial liabilities			Other			Adjusted
Diagnostic test revenue	$	99,823		$	—		$	—		$	—		$	—		$	—		$	99,823
Other revenue		2,869			—			—			—			—			—			2,869
Total revenue		102,692			—			—			—			—			—			102,692
Cost of services		31,790			(1,389	)		(193	)		—			—			—			30,208
Gross profit (loss)		70,902			1,389			193			—			—			—			72,484
Gross margin		69.0	%																	70.6	%

Research and development		15,079			(209	)		(1,422	)		—			—			—			13,448
Selling and marketing		19,448			(1,298	)		(1,268	)		—			—			—			16,882
General and administrative		27,415			(3,295	)		(4,930	)		(73	)		—			8,342			27,459

Loss from operations		8,960			6,191			7,813			73			—			(8,342	)		14,695

Interest income (expense), net		(817	)		—			—			—			—			817			—
Other income (expense), net		2,420			—			—			—			(2,181	)		49			288
Income tax benefit		246			—			—			—			—			(246	)		—
Net income	$	10,809		$	6,191		$	7,813		$	73		$	(2,181	)	$	(7,722	)	$	14,983

Basic earnings per share*	$	0.38																	$	0.52
Diluted earnings per share*	$	0.36																	$	0.50
* Basic and diluted earnings per share are calculated based on 28,579,704 and 29,753,933 weighted average shares outstanding for the three months ended June 30, 2025, respectively.

	Three months ended June 30, 2024
	Reported			Depreciation and amortization			Stock-based compensation expense			Restructuring costs			Change in FV of financial liabilities		Other¹			Adjusted
Diagnostic test revenue	$	69,439		$	—		$	—		$	—		$	—	$	—		$	69,439
Other revenue		1,075			—			—			—			—		—			1,075
Total revenue		70,514			—			—			—			—		—			70,514
Cost of services		27,562			(808	)		(86	)		—			—		—			26,668
Gross profit (loss)		42,952			808			86			—			—		—			43,846
Gross margin		60.9	%																62.2	%

Research and development		10,902			(211	)		(347	)		(35	)		—		—			10,309
Selling and marketing		16,585			(1,225	)		(368	)		(63	)		—		—			14,929
General and administrative		26,044			(2,974	)		(2,307	)		(150	)		—		—			20,613

Loss from operations		(10,579	)		5,218			3,108			248			—		—			(2,005	)

Interest income (expense), net		(894	)		—			—			—			—		894			—
Other income (expense), net		(17,890	)		—			—			—			4,409		13,450			(31	)
Income tax benefit		190			—			—			—			—		(190	)		—
Net loss	$	(29,173	)	$	5,218		$	3,108		$	248		$	4,409	$	14,154		$	(2,036	)

Basic loss per share*	$	(1.10	)															$	(0.08	)
Diluted loss per share*	$	(1.10	)															$	(0.08	)
* Basic and diluted loss per share are calculated based on 26,617,955 diluted weighted average shares outstanding for the three months ended June 30, 2024.
Other represents interest expense, net, and income tax (expense) benefit for all periods presented. Other for the three months ended June 30, 2025 includes transaction costs related to the acquisition of Fabric Genomics. Other for the three months ended June 30, 2024 includes legal costs related to a legal settlement.

GeneDx Holdings Corp. Condensed Consolidated Balance Sheets (in thousands, except share and per share amounts)
	June 30, 2025 (Unaudited)			December 31, 2024
Assets:
Current assets:
Cash and cash equivalents	$	74,120		$	85,212
Marketable securities		60,438			55,973
Accounts receivable		48,028			37,629
Inventory, net		11,932			10,650
Prepaid expenses and other current assets		10,319			8,504
Total current assets		204,837			197,968
Operating lease right-of-use assets		24,978			25,613
Property and equipment, net		40,120			32,893
Goodwill		12,926			—
Intangible assets, net		176,689			158,600
Other assets¹		4,313			4,306
Total assets	$	463,863		$	419,380
Liabilities and Stockholders’ Equity:
Current liabilities:
Accounts payable and accrued expenses	$	49,239		$	30,983
Short-term lease liabilities		3,083			3,336
Other current liabilities		19,084			20,498
Total current liabilities		71,406			54,817
Long-term debt, net of current portion		51,683			51,913
Long-term lease liabilities		59,619			60,919
Other liabilities		3,275			5,519
Deferred taxes		747			965
Total liabilities		186,730			174,133
Stockholders’ Equity:
Preferred stock		—			—
Class A common stock		2			2
Additional paid-in capital		1,624,513			1,596,889
Accumulated deficit		(1,348,194	)		(1,352,474	)
Accumulated other comprehensive income		812			830
Total stockholders’ equity		277,133			245,247
Total liabilities and stockholders’ equity	$	463,863		$	419,380
Other assets includes $990 thousand of restricted cash as of both June 30, 2025 and December 31, 2024.

GeneDx Holdings Corp. Condensed Consolidated Statements of Operations (Unaudited) (in thousands, except share and per share amounts)
	Three months ended June 30,						Six months ended June 30,
		2025			2024			2025			2024
Revenue
Diagnostic test revenue	$	99,823		$	69,439		$	185,582		$	130,543
Other revenue		2,869			1,075			4,225			2,393
Total revenue		102,692			70,514			189,807			132,936
Cost of services		31,790			27,562			60,429			52,573
Gross profit		70,902			42,952			129,378			80,363
Research and development		15,079			10,902			27,656			22,469
Selling and marketing		19,448			16,585			37,764			32,670
General and administrative		27,415			26,044			59,549			49,463
Income (loss) from operations		8,960			(10,579	)		4,409			(24,239	)

Non-operating income (expenses), net
Change in fair value of warrants and contingent liabilities		2,181			(4,409	)		1,081			(10,510	)
Interest expense, net		(817	)		(894	)		(1,457	)		(1,491	)
Other income (expense), net		239			(13,481	)		448			(13,444	)
Total non-operating income (expense), net		1,603			(18,784	)		72			(25,445	)
Income (loss) before income taxes		10,563			(29,363	)	$	4,481		$	(49,684	)
Income tax benefit (expense)		246			190			(201	)		272
Net income (loss)	$	10,809		$	(29,173	)	$	4,280		$	(49,412	)

Weighted average shares outstanding of Class A common stock - Basic		28,579,704			26,617,955			28,365,018			26,340,063
Earnings (loss) per share, Class A common stock- Basic	$	0.38		$	(1.10	)	$	0.15		$	(1.88	)
Weighted average shares outstanding of Class A common stock - Diluted		29,753,933			26,617,955			29,642,555			26,340,063
Earnings (loss) per share, Class A common stock- Diluted	$	0.36		$	(1.10	)	$	0.14		$	(1.88	)

GeneDx Holdings Corp. Condensed Consolidated Statements of Cash Flows (Unaudited) (in thousands)
	Six months ended June 30,
		2025			2024
Operating activities
Net income (loss)	$	4,280		$	(49,412	)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization expense		11,869			10,466
Stock-based compensation expense		11,796			2,657
Change in fair value of warrants and contingent liabilities		(1,081	)		10,510
Deferred tax expense (benefit)		202			(272	)
Provision for excess and obsolete inventory		123			109
Legal reserves		—			13,450
Change in third party payor reserves		5,014			1,066
Other		1,387			1,738
Change in operating assets and liabilities:
Accounts receivable		(9,889	)		6,622
Inventory		(1,404	)		(1,654	)
Accounts payable and accrued expenses		7,199			(10,871	)
Other assets and liabilities		(8,894	)		(5,327	)
Net cash provided by (used in) operating activities		20,602			(20,918	)
Investing activities
Acquisition of business, net of cash acquired		(33,195	)		—
Purchases of property and equipment		(8,498	)		(1,795	)
Purchases of marketable securities		(30,770	)		(29,381	)
Proceeds from sales of marketable securities		—			598
Proceeds from maturities of marketable securities		26,705			8,720
Net cash used in investing activities		(45,758	)		(21,858	)
Financing activities
Proceeds from offerings, net of issuance costs		13,766			—
Proceeds from issuance of common stock pursuant to employee stock purchase plan		1,262			—
Exercise of stock options		800			161
Long-term debt principal payments		(602	)		—
Finance lease principal payments		(1,162	)		(990	)
Net cash provided by (used in) financing activities		14,064			(829	)
Net decrease in cash, cash equivalents and restricted cash		(11,092	)		(43,605	)
Cash, cash equivalents and restricted cash, at beginning of period		86,202			100,668
Cash, cash equivalents and restricted cash, at end of period ⁽¹⁾	$	75,110		$	57,063

Supplemental disclosures of cash flow information
Cash paid for interest	$	3,210		$	4,033
Cash paid for taxes	$	920		$	557
Stock consideration paid pursuant to exercise of Perceptive warrant	$	—		$	12,586
Purchases of property and equipment in accounts payable and accrued expenses	$	5,752		$	501
Assets acquired under capital lease obligations	$	—		$	689
Cash, cash equivalents and restricted cash at June 30, 2025 excludes marketable securities of $60.4 million.

Stock Quote

Last Trade:	US$101.60
Daily Change:	-0.35 -0.34
Daily Volume:	845,650
Market Cap:	US$2.900B

June 25, 2025 GeneDx Announces Publication of SeqFirst Study Demonstrating Need for First Tier Rapid Genomic Testing for Non-Critical Care Pediatric Inpatients in The Journal of Pediatrics June 23, 2025 GeneDx Announces American Academy of Pediatrics Recommends Exome and Genome Sequencing as First-Tier Tests for Children with Global Developmental Delay or Intellectual Disability June 23, 2025 GeneDx: Galatea Bio and Fabric Genomics Partner to Deliver Comprehensive Genetic Testing for Common Diseases May 22, 2025 GeneDx Publishes Pioneering Vision for Applying AI to Genomics to Improve and Expedite Diagnosis of Genetic Disease at Scale April 30, 2025 GeneDx Reports First Quarter 2025 Financial Results and Business Highlights LOAD MORE NEWS

Featured Stock

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE